Health Trials

Prostate Adenocarcinoma With Neuroendocrine Differentiation

1

Review clinical trials related to Prostate Adenocarcinoma With Neuroendocrine Differentiation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and Tagitanlimab (KL-A167) in the treatment of AVPC (aggressive variant prostate cancer) and NEPC (neuroendocrine prostate cancer).

Participants needed: 28
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Tianjin Medical University Second HospitalUpdated: Sep 18, 2025Locations: 1
Eligibility criteria

Age at the time of signing the informed consent form is ≥ 18 years old; [+12]

Targeted treatment of TROP2; [+29]

Read more